Xenon Pharmaceuticals (XENE) Interest Expenses (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Interest Expenses data on file, last reported at $8.3 million in Q1 2026.

• On a quarterly basis, Interest Expenses fell 15.05% year-over-year to $8.3 million in Q1 2026; TTM through Mar 2026 was $8.3 million, a 15.05% decrease from a year earlier, with the FY2025 full-year figure at $346.8 million, up 211.86% from the prior year.
• Interest Expenses for Q1 2026 stood at $8.3 million, up from $434000.0 in the prior quarter.
• Over the last five years, Interest Expenses for XENE reached as high as $12.7 million in Q3 2023 and fell as low as $281000.0 in Q4 2022.
• Historically, Interest Expenses has averaged $5.6 million across 5 years, with a median of $2.3 million in 2023.
• Across the five-year window, Interest Expenses jumped 1915.97% in 2022 and sank 90.96% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $281000.0 in 2022, then soared by 44.13% to $405000.0 in 2023, then grew by 5.43% to $427000.0 in 2024, then advanced by 1.64% to $434000.0 in 2025, then surged by 1806.68% to $8.3 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $8.3 million in Q1 2026, $434000.0 in Q4 2025, and $9.3 million in Q3 2025.